Press Releases

 

Ovation Study/Ovarian Cancer

  Date Title and Summary View
Jan 6, 2015
LAWRENCEVILLE, N.J., Jan. 6, 2015 /PRNewswire/ -- Celsion Corporation (Celsion) (NASDAQ:CLSN), a fully-integrated oncology company focused on the development of a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies for the treatment of cancer and other difficult-to-treat dise...
Jun 1, 2015
LAWRENCEVILLE, N.J., June 1, 2015 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), a fully integrated oncology drug development company, announced the presentation of clinical results from its Phase IB trial for GEN-1 in platinum-resistant ovarian cancer in a poster session by Dr. Premal H. Thaker, M.D., associate professor at Washington Univers...
Sep 30, 2015
LAWRENCEVILLE, N.J., Sept. 30, 2015 /PRNewswire/ -- Celsion Corporation (Celsion) (NASDAQ:CLSN), a fully-integrated oncology company focused on the development of a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies for the treatment of cancer and other difficult-to-treat di...
Oct 12, 2015
LAWRENCEVILLE, N.J., Oct. 12, 2015 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today reported data from a large preclinical study of the Company's GEN-1 IL-12 immunotherapy in combination with Avastin® and Doxil® for the treatment of ovarian cancer. Results from the comprehensive studies confi...
Apr 12, 2016
LAWRENCEVILLE, N.J., April 12, 2016 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that data highlighting the potential of GEN-1 in ovarian cancer will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting, which is being held in New Orleans from April ...
May 2, 2016
LAWRENCEVILLE, N.J., May 2, 2016 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced data from the first cohort of patients in its Phase Ib dose escalating clinical trial (the OVATION Study) combining GEN-1, the Company's DNA-based immunotherapy, with the standard of care for the treatment of ne...
May 24, 2016
LAWRENCEVILLE, N.J., May 24, 2016 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today provided an update on its ongoing OVATION study, a Phase Ib dose escalating clinical trial combining GEN-1, the Company's DNA-based immunotherapy, with the standard of care for the treatment of newly-diagnosed patients w...
Jul 25, 2016
LAWRENCEVILLE, N.J., July 25, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) today announced data from the second cohort of patients in its Phase Ib dose escalating clinical trial (the OVATION Study) combining GEN-1, the Company's DNA-based immunotherapy, with the standard of care for the treatment of newly-diagnosed patients with adv...
Sep 15, 2016
LAWRENCEVILLE, N.J., Sept. 15, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) today announced that the independent Data Safety Monitoring Board (DSMB) has completed its safety review of data from the first three patient cohorts in the ongoing Phase Ib OVATION Study.  Based on the DSMB's recommendation, the study will continue as plann...
Nov 10, 2016
Third Cohort of Patients Continues to Show Clinically Meaningful Responses in the Evaluation of GEN-1, A Novel IL-12 DNA-based Immunotherapy, in Combination with the Standard of Care Top Line Translational Data from First Two Cohorts Demonstrates Potential Immune Activation LAWRENCEVILLE, N.J., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Celsion Corp...
Page:
1
NextLast
= add release to Briefcase
Share This